gabapentin has been researched along with Adverse Drug Event in 17 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy and safety of gabapentin and oral antidepressants in patients with chronic pruritus in daily clinical practice." | 8.31 | Gabapentin and oral antidepressants for chronic pruritus: a prospective cohort study evaluating efficacy and side effects in daily dermatological practice. ( Kamsteeg, M; Kouwenhoven, TA; van de Kerkhof, PCM, 2023) |
| "Treatment options for postherpetic neuralgia (PHN), a complication of herpes zoster, are commonly unsatisfactory and associated with adverse events." | 6.78 | Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. ( Irving, GA; Rauck, RL; Sweeney, M; Vanhove, GF; Wallace, MS, 2013) |
| " Overall, there was a low quality of evidence that gabapentin, pregabalin, amitriptyline, and venlafaxine were effective in reducing pain intensity in patients with cancer pain." | 4.95 | Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review. ( de Graeff, A; Dijkstra, D; Jongen, JL; Mostovaya, I; van den Beuken-van Everdingen, MH; Vissers, KC, 2017) |
| "To evaluate the efficacy and safety of gabapentin and oral antidepressants in patients with chronic pruritus in daily clinical practice." | 4.31 | Gabapentin and oral antidepressants for chronic pruritus: a prospective cohort study evaluating efficacy and side effects in daily dermatological practice. ( Kamsteeg, M; Kouwenhoven, TA; van de Kerkhof, PCM, 2023) |
| "In this analysis of the Italian spontaneous reporting system database, we found new urinary retention signals, requiring further evaluation, for dapagliflozin, gabapentin, lithium, celecoxib, and piroxicam." | 4.12 | Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database. ( Crisafulli, S; Cutroneo, PM; Di Giovanni, V; Ferrajolo, C; Ficarra, V; Sottosanti, L; Spina, E; Trifirò, G; Verhamme, K, 2022) |
| "Treatment options for postherpetic neuralgia (PHN), a complication of herpes zoster, are commonly unsatisfactory and associated with adverse events." | 2.78 | Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. ( Irving, GA; Rauck, RL; Sweeney, M; Vanhove, GF; Wallace, MS, 2013) |
| "We examined systematic adverse events (AEs) in Part 1 (of 2) of a study describing the assessment and reporting of AEs in clinical trials." | 2.61 | Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events. ( Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2019) |
| "We examined nonsystematic adverse events (AEs) in Part 2 (of 2) of a study describing the assessment and reporting AEs in clinical trials." | 2.61 | Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. ( Canner, JK; Dickersin, K; Fusco, N; Hong, H; Li, T; Mayo-Wilson, E, 2019) |
| "Gabapentin was significantly less likely to be prescribed to Black or Hispanic patients, and more likely to be prescribed to female patients, those with co-occurring substance use or mood disorders, and those with comorbid physical conditions such as neuropathic pain." | 1.91 | Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder. ( Buttram, ME; Ellis, MS; Fidalgo, TM; Grucza, RA; Tardelli, VS; Xu, KY, 2023) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Yamada, T | 1 |
| Mitsuboshi, S | 1 |
| Makino, J | 1 |
| Suzuki, K | 1 |
| Nishihara, M | 1 |
| Neo, M | 1 |
| Ellis, MS | 1 |
| Xu, KY | 1 |
| Tardelli, VS | 1 |
| Fidalgo, TM | 1 |
| Buttram, ME | 1 |
| Grucza, RA | 1 |
| Kouwenhoven, TA | 1 |
| van de Kerkhof, PCM | 1 |
| Kamsteeg, M | 1 |
| Crisafulli, S | 1 |
| Cutroneo, PM | 1 |
| Verhamme, K | 1 |
| Ferrajolo, C | 1 |
| Ficarra, V | 1 |
| Sottosanti, L | 1 |
| Di Giovanni, V | 1 |
| Spina, E | 1 |
| Trifirò, G | 1 |
| Peckham, AM | 1 |
| Fairman, KA | 1 |
| Sclar, DA | 1 |
| Mayo-Wilson, E | 2 |
| Fusco, N | 2 |
| Li, T | 2 |
| Hong, H | 2 |
| Canner, JK | 2 |
| Dickersin, K | 2 |
| Kottschade, L | 1 |
| Novotny, P | 1 |
| Lyss, A | 1 |
| Mazurczak, M | 1 |
| Loprinzi, C | 1 |
| Barton, D | 1 |
| van den Beuken-van Everdingen, MH | 1 |
| de Graeff, A | 1 |
| Jongen, JL | 1 |
| Dijkstra, D | 1 |
| Mostovaya, I | 1 |
| Vissers, KC | 1 |
| Melvin, CL | 2 |
| Carey, TS | 1 |
| Goodman, F | 1 |
| Oldham, JM | 1 |
| Williams, JW | 1 |
| Ranney, LM | 2 |
| Kish-Doto, J | 1 |
| Evans, WD | 1 |
| Squire, C | 1 |
| Williams, P | 1 |
| Tsavaris, N | 1 |
| Kopterides, P | 1 |
| Kosmas, C | 1 |
| Efthymiou, A | 1 |
| Skopelitis, H | 1 |
| Dimitrakopoulos, A | 1 |
| Pagouni, E | 1 |
| Pikazis, D | 1 |
| Zis, PV | 1 |
| Koufos, C | 1 |
| Sandercock, D | 1 |
| Cramer, M | 1 |
| Biton, V | 1 |
| Cowles, VE | 1 |
| Rauck, RL | 1 |
| Irving, GA | 1 |
| Wallace, MS | 1 |
| Vanhove, GF | 1 |
| Sweeney, M | 1 |
| Elger, CE | 1 |
| Bauer, J | 1 |
| Scherrmann, J | 1 |
| Widman, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PUCE Study: Prevention of Unmitigated Chemotherapy-induced Emesis[NCT03996863] | 0 participants (Actual) | Interventional | 2019-08-01 | Withdrawn (stopped due to Drexel Oncology was shut down a few days before first patient in.) | |||
| Hypogastric Plexus Block and Ganglion Impar Block for Cervical and Endometrial Cancer Pain Management: A Randomized Controlled Trial of Efficacy and Safety[NCT05427058] | 36 participants (Anticipated) | Interventional | 2022-08-01 | Not yet recruiting | |||
| Auricular Point Acupressure to Manage Chemotherapy Induced Neuropathy[NCT04920097] | 240 participants (Anticipated) | Interventional | 2021-07-08 | Recruiting | |||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy[NCT00712439] | Phase 2 | 147 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for gabapentin and Adverse Drug Event
| Article | Year |
|---|---|
Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events.
Topics: Bipolar Disorder; Data Accuracy; Drug-Related Side Effects and Adverse Reactions; Gabapentin; Humans | 2019 |
Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events.
Topics: Bipolar Disorder; Data Accuracy; Drug-Related Side Effects and Adverse Reactions; Gabapentin; Humans | 2019 |
Pharmacological Treatment of Pain in Cancer Patients: The Role of Adjuvant Analgesics, a Systematic Review.
Topics: Amines; Analgesics; Anticonvulsants; Antidepressive Agents; Chemotherapy, Adjuvant; Cyclohexanecarbo | 2017 |
Effectiveness of antiepileptic drugs for the treatment of bipolar disorder: findings from a systematic review.
Topics: Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug-Related Side Effects an | 2008 |
Aggravation of focal epileptic seizures by antiepileptic drugs.
Topics: Acetates; Acute Disease; Adult; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarbox | 1998 |
3 trials available for gabapentin and Adverse Drug Event
| Article | Year |
|---|---|
Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).
Topics: Adult; Aged; Amines; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclohexanecarboxylic Acids; Dru | 2016 |
A gastroretentive gabapentin formulation for the treatment of painful diabetic peripheral neuropathy: efficacy and tolerability in a double-blind, randomized, controlled clinical trial.
Topics: Aged; Algorithms; Amines; Analgesics; Chemistry, Pharmaceutical; Cyclohexanecarboxylic Acids; Diabet | 2012 |
Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
Topics: Amines; Analgesics; Causality; Comorbidity; Cyclohexanecarboxylic Acids; Disorders of Excessive Somn | 2013 |
9 other studies available for gabapentin and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Risk of Pregabalin-Induced Hypoglycemia: Analysis of the Japanese Adverse Drug Event Report Database.
Topics: Aged; Drug-Related Side Effects and Adverse Reactions; Duloxetine Hydrochloride; Gabapentin; Humans; | 2022 |
Gabapentin Use Among Individuals Initiating Buprenorphine Treatment for Opioid Use Disorder.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Case-Control Studies; Drug-Related Side Effects and Advers | 2023 |
Gabapentin and oral antidepressants for chronic pruritus: a prospective cohort study evaluating efficacy and side effects in daily dermatological practice.
Topics: Adult; Amines; Antidepressive Agents; Cohort Studies; Cyclohexanecarboxylic Acids; Drug-Related Side | 2023 |
Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database.
Topics: Adverse Drug Reaction Reporting Systems; Celecoxib; Drug-Related Side Effects and Adverse Reactions; | 2022 |
Call for increased pharmacovigilance of gabapentin.
Topics: Adverse Drug Reaction Reporting Systems; Amines; Cyclohexanecarboxylic Acids; Drug-Related Side Effe | 2017 |
Patterns of prescribing antiepileptic drugs for bipolar disorder.
Topics: Adult; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Drug-Related Side Eff | 2008 |
Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Drug-Related Side Effects and Adverse | 2008 |